Clinical Trial
51
1
3
32
Key Insights
Highlights
Success Rate
97% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
2.0%
1 terminated out of 51 trials
97.0%
+10.5% vs benchmark
18%
9 trials in Phase 3/4
6%
2 of 32 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 32 completed trials
Clinical Trials (51)
Optimal Dosage of Melatonin for Preoperative Sedation in FESS
GOREISAN for Heart Failure (GOREISAN-HF) Trial
Efficacy of iPSC-Derived Motor Neuron Cells (XS228) in Subacute Spinal Cord Injury: A Phase II Randomized Controlled Trial
Primary Care Evidence-based Approach for Improving Lifelong Health
Clinical Evaluation of Class I Direct and Indirect Restorations Over 10 Years
Microencapsulated Pomegranate Juice as Anti-Hypertensive
Dual-Task Exercise for Mild Traumatic Brain Injury (mTBI)
AFRI Childhood Obesity Prevention Challenge Area
Comparison of Modified Vacuum-formed Retainers Versus Hawley Retainer
Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae
tDCS as Adjunctive Therapy to Cognitive Stimulation in Medical Students With Depression
A Multicentre, Randomised, Single-blind, Controlled Protocol to Evaluate the Efficacy of Early Administration of Botulinum Toxin for Primary Midline Closure in Patients With Open Abdomen.
Th Tl Xb Prescription on Reprogramming of Lipid Metabolism and Endothelial Injury for Cerebral Infarction Patients
Raising Healthy Children: A Hybrid Trial of the Family Check-Up 4 Health in Primary Care
Safety and Efficacy of Drug-Coated Balloon for De-novo Lesions in Patients With Acute Coronary Syndromes (DCB-ACS)
Weight Loss in Patients With COVID-19 and Influenza in Comorbidity With NCDs: a Pilot Prospective Clinical Trial
Evaluation of Pharmacokinetics and Safety Tolerability of Higher Doses of Rifampic
Supplementation Performance And Exercise With Euterpe Edulis for Men's Enhancement
Dietary Intervention to Reduce Metabolic Endotoxemia
Impact of Evolocumab as an Additional Lipid-lowering Therapy to Changes in Lipid Core Burden Index of Non-culprit Vulnerable Plaque in Patients Who Underwent Percutaneous Coronary Intervention for the Acute Coronary Syndrome